Zydus Lifesciences Ltd (ZYDUSLIFE) is currently trading at 1,190.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Zydus Lifesciences is an innovation-led life-sciences company spanning branded and generic pharmaceuticals, specialty medicines, biosimilars, APIs, consumer wellness and emerging MedTech, with operations across India, the United States and international markets. Its integrated model covers research, manufacturing, regulatory development, marketing and commercialization, supported by approximately 30,000 employees and 1,500 scientists. Q2 FY27 revenue grew 29% year-on-year to Rs. 79,096 million, but EBITDA declined 6% and net profit fell 27%, indicating substantial margin and earnings pressure despite strong top-line momentum. EBITDA margin compressed to 24.0% from 32.9% in the prior-year quarter, making profitability recovery a central monitoring point. Growth is increasingly diversified beyond traditional pharmaceuticals. Consumer Wellness revenue rose 76% year-on-year and MedTech revenue increased 47% in Q2, while International Markets formulations grew 33%; however, North America remains the largest business, contributing 43% of consolidated revenue and retaining significant influence over group performance. Zydus is shifting toward differentiated and specialty-led products, with branded sales reaching 16% of US revenue and continued momentum from Rolvedon and the 505(b)(2) portfolio. The anticipated US approval and launch of Saroglitazar would represent a major strategic milestone as the company’s first indigenously discovered new chemical entity. The company continues to invest heavily in future growth, spending Rs. 6,573 million on R&D and Rs. 4,655 million on organic capex during Q2. Its pipeline includes Saroglitazar, a monoclonal antibody entering Phase III development in India, a pembrolizumab biosimilar under US review and Alvelestat licensed for further development.

Over the past 52 weeks, Zydus Lifesciences Ltd has traded between a low of ₹835.85 and a high of ₹1,266.15. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Zydus Lifesciences Ltd has a market capitalization of approximately 1,23,590.72. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Zydus Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 29.52 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 1,23,590.72 Cr, Zydus Lifesciences Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Zydus Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Zydus Lifesciences Ltd is 29.52. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Zydus reported consolidated net profit of ₹925.5 crore for Q2 FY27. This was 26.6% lower than ₹1,260.9 crore reported in the corresponding quarter of FY26.

Zydus extended the deadline because Sterling Biotech is still working to fulfil conditions precedent under the business transfer agreement. Both parties mutually agreed to set September 30, 2026 as the revised closing date.

The FDA accepted for review the Biologics License Application (BLA) for FYB206, a proposed biosimilar to Keytruda (pembrolizumab).

Zydus said saroglitazar (1 mg) met the primary endpoint at 52 weeks, delivering a 48.5% treatment difference versus placebo and higher biochemical response (56.7% vs 9.8%).